Literature DB >> 11839650

Expression profile of tyrosine kinases in breast cancer.

Funda Meric1, Wei-Ping Lee, Aysegul Sahin, Haixia Zhang, Hsing-Jien Kung, Mien-Chie Hung.   

Abstract

The tyrosine kinase (TK) family includes many growth factor receptors, cell cycle regulators, and oncoproteins. Moreover, the receptor TKs HER2/neu and epidermal growth factor receptor are overexpressed in a subgroup of breast tumors and correlate with more aggressive behavior. Thus, TKs are being actively pursued as therapeutic targets. The purpose of this study was to determine the expression pattern of TKs in breast cancer. Reverse transcription-PCR was performed with degenerate primers based on conserved motifs of the catalytic domains of TKs, and the identities of the reverse transcription-PCR products were determined by digestion with a panel of restriction enzymes. Using a TK display assay, we studied the TK profiles of 13 breast cancer cell lines and two normal immortalized breast epithelial cell lines. The TK display assay reproducibly demonstrated known differences in HER-2/neu expression between cell lines. Several TKs, including receptor TKs Axl, Cak, fibroblast growth factor receptor 4, HEK8, HER2/neu, c-MET, RET, and nonreceptor TKs ARG, BRK, Janus kinase 1, Rak, and YES were detected in breast cancer cells. Several kinases were differentially expressed among the cell lines. Similar TK profiles were found using RNA from human breast tumors. We conclude that there is significant variability in the TK expression pattern of breast cancers. This variability should be considered when selecting TK inhibitors to treat patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11839650

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  55 in total

1.  Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma.

Authors:  Xianzhou Song; Hua Wang; Craig D Logsdon; Asif Rashid; Jason B Fleming; James L Abbruzzese; Henry F Gomez; Douglas B Evans; Huamin Wang
Journal:  Cancer       Date:  2010-10-04       Impact factor: 6.860

2.  The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.

Authors:  Jennifer L Dine; Ciara C O'Sullivan; Donna Voeller; Yoshimi E Greer; Kathryn J Chavez; Catherine M Conway; Sarah Sinclair; Brandon Stone; Laleh Amiri-Kordestani; Anand S Merchant; Stephen M Hewitt; Seth M Steinberg; Sandra M Swain; Stanley Lipkowitz
Journal:  Breast Cancer Res Treat       Date:  2016-01-12       Impact factor: 4.872

Review 3.  Critical signal transduction pathways in CLL.

Authors:  Asish K Ghosh; Neil E Kay
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

4.  Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.

Authors:  Mark Mackiewicz; Konrad Huppi; Jason J Pitt; Tiffany H Dorsey; Stefan Ambs; Natasha J Caplen
Journal:  Breast Cancer Res Treat       Date:  2011-08-04       Impact factor: 4.872

5.  Off-target effects of c-MET inhibitors on thyroid cancer cells.

Authors:  Yan Zhou; Conghui Zhao; Sigal Gery; Glenn D Braunstein; Ryoko Okamoto; Rocio Alvarez; Steven A Miles; Ngan B Doan; Jonathan W Said; Jiang Gu; H Phillip Koeffler
Journal:  Mol Cancer Ther       Date:  2013-10-29       Impact factor: 6.261

6.  Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival.

Authors:  Peter Vajkoczy; Pjotr Knyazev; Andrea Kunkel; Hans-Holger Capelle; Sandra Behrndt; Hendrik von Tengg-Kobligk; Fabian Kiessling; Uta Eichelsbacher; Marco Essig; Tracy-Ann Read; Ralf Erber; Axel Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

7.  Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis.

Authors:  Yong Liao; Mien-Chie Hung
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

8.  Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin.

Authors:  Hsin-Yi Chen; Che-Hung Shen; Yuh-Tyng Tsai; Feng-Chi Lin; Yuan-Ping Huang; Ruey-Hwa Chen
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

9.  Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.

Authors:  Kinga Pénzes; Christine Baumann; István Szabadkai; László Orfi; György Kéri; Axel Ullrich; Robert Torka
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

10.  Activated tyrosine kinases in gastrointestinal stromal tumor with loss of KIT oncoprotein expression.

Authors:  Yuqing Tu; Rui Zuo; Nan Ni; Grant Eilers; Duolin Wu; Yuting Pei; Zuoming Nie; Yeqing Wu; Yuehong Wu; Wen-Bin Ou
Journal:  Cell Cycle       Date:  2018-12-04       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.